To assess the effect of CC-885 on BNIP3L-mediated mitophagy.
Acta Pharmacol Sin. 2020 Sep;41(9):1246-1254
HEK293T cells
1 μM
24 h
To verify whether CC-885-induced BNIP3L protein degradation is CRBN-dependent.
Acta Pharmacol Sin. 2020 Sep;41(9):1246-1254
A549 cells
200 nM
12 h
To identify potential neosubstrates of CC-885 in A549 cells using quantitative proteomics analysis.
Acta Pharmacol Sin. 2020 Sep;41(9):1246-1254
NCI-H1299 cells
50 nM
24 h
This synergistic effect was also obtained in another NSCLC cell line, NCI-H1299.
Mol Ther Oncolytics. 2020 Jun 23;18:215-225
A549 cells
50 nM
24 h
CC-885 synergistically enhanced volasertib-induced cell death in NSCLC identified by IMiD drug screen.
Mol Ther Oncolytics. 2020 Jun 23;18:215-225
U87 glioblastoma cells
100 nM
16 h
To confirm the ubiquitination effect of CC-885 on GSPT1 via the E3 ubiquitin ligase complex (CRL4CBRN)
Cell Death Dis. 2024 Aug 8;15(8):572
LX2 cells
1 μM
24 h
To evaluate the inhibitory effect of CC-885 on BNC2 expression, results showed CC-885 significantly reduced BNC2 protein levels
Nat Commun. 2022 Sep 10;13(1):5324
HDQ-P1 cells
10 nM
72 h
CC-885 efficiently reduced eRF3a levels starting a few h after compound addition and reaching >90% reduction within 24h.
Nucleic Acids Res. 2021 Apr 19;49(7):3692-3708
CC-885 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
BALB/cA nude mice
A549 xenograft model
Intraperitoneal injection
20 mg/kg
Three times per week for four weeks
While volasertib and CC-885 alone inhibited tumor growth, the combination of both small molecular drugs markedly inhibited tumor growth and reduced tumor weights.
Mol Ther Oncolytics. 2020 Jun 23;18:215-225
Nude mice
U87 glioblastoma cell transplanted brain tumor model
Intraperitoneal injection
50 mg/kg and 100 mg/kg
Once every alternate day, total of 4 times
To assess the therapeutic effect of CC-885 on transplanted brain tumors, showing significantly prolonged survival and reduced tumor size
搜索
